Spots Global Cancer Trial Database for Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
Official Title: Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
Study ID: NCT01795313
Conditions
Study Description
Brief Summary: The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Detailed Description:
Keywords
Eligibility
Minimum Age: 12 Months
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Contact Details
Name: James Felker, MD
Affiliation: University of Pittsburgh
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
